drug · antibody drug conjugate
pivekimab sunirine
pre_registrationupdated 3mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Phase 1 2 (across all indications), with 3 investigational indications.
targets
Interleukin-3 receptor subunit alpha
all catalysts(0)
nothing on the calendar yet
Trials studying pivekimab sunirine
- phase3A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- phase1Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
- phase1A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that